DigestRedComo funciona
Red
/
Empresas
Te
No verificado

Teva Pharmaceutical Industries Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

77 Comunicados de prensa

Ver todos los comunicados de prensa
12/12/2025
Farmacéutica
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
12/12/2025
Farmacéutica
Medicina Salud Bienestar
Teva Releases Q4 2025 Aide Memoire
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/12/2025
Farmacéutica
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
25/11/2025
Farmacéutica
Anuncios breves
Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
25/11/2025
Farmacéutica
Anuncios breves
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
21/11/2025
Farmacéutica
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
19/11/2025
Farmacéutica
Anuncios breves
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
07/11/2025
Farmacéutica
Medicina Salud Bienestar
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
05/11/2025
Farmacéutica
Gestión empresarial/Administración de Empresas
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
03/11/2025
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0